CLEVELAND, Feb. 7, 2018 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY), maker of the world's first and only clinical
MRI-guided radiation therapy system, announced today the
appointment of medical device industry veterans Scott Huennekens and Daniel Moore to the Company's board of
directors, effective immediately. Mr. Huennekens currently serves
as chairman, president, and chief executive officer of Verb
Surgical, a joint venture between Ethicon, a medical device company
in the Johnson & Johnson family of companies, and Verily
Life Sciences (formerly Google Life Sciences) in the field of
robotic surgery. Mr. Moore currently serves as chairman of the
board for LivaNova PLC, having previously served as chief executive
officer of Cyberonics, Inc. prior to its merger with Sorin S.p.A.
in 2015 to create LivaNova.
The Company also announced the impending resignations of two
directors: David Bonita, M.D., and
Mark S. Gold, M.D. Both Dr. Bonita
and Dr. Gold announced their intention to step down from the Board
at the Company's Annual Meeting.
"We are delighted to welcome Dan and Scott to our board of
directors," said Chris A. Raanes,
president and chief executive officer of ViewRay. "We believe
that Dan and Scott's deep operational experience with fast-growing
medical device companies will be invaluable as we seek to bring the
benefits of the MRIdian Linac system to patients around the
world."
Mr. Raanes continued, "I would also like to thank Dr.
Mark Gold and Dr. David Bonita for their many years of service to
ViewRay. Mark has been a member of the board since the early
stages of the Company and David led our first institutional
financing. Their extensive experience and dedication to ViewRay
have been enormously helpful as we have grown from a dream to a
reality."
Mr. Huennekens is currently chairman, president and chief
executive officer of Verb Surgical, which he joined in August 2015. Previously, Mr. Huennekens served as
president and chief executive officer of Volcano Corporation from
its start-up in 2002, through its IPO in 2006, and to its eventual
sale to Royal Philips in 2015. Prior
to his work at Volcano, Mr. Huennekens served as president and
chief executive officer of Digirad Corporation, a diagnostic
imaging solutions provider. Mr. Huennekens is a board member and
past chairman of the Medical Device Manufacturer's Association
(MDMA). He graduated magna cum laude with a Bachelor of Science in
Business Administration from the University of
Southern California in 1986 and earned his Masters of
Business Administration from the Harvard
Business School in 1991.
Mr. Moore has served as Chairman of LivaNova's board of
directors since 2015. Previously he served as a member of the board
and chief executive officer of Cyberonics from 2007. Mr. Moore
joined Cyberonics from Boston Scientific, where he held positions
in sales, marketing and senior management in the U.S. and in
Europe. His last position at
Boston Scientific was president, International Distributor
Management. Prior to that role, he held the position of president,
Inter-Continental, a business unit of Boston Scientific. Mr.
Moore earned a Bachelor of Arts from Harvard
University, and a Masters of Business Administration with
High Honors from Boston University.
As non-employee directors, Mr. Huennekens, who will join as a
class III director, and Mr. Moore, who will join as a class II
director, will each receive initial option grants with an aggregate
grant date fair value of $176,400 of
the Company's common stock, pursuant to the terms of the Company's
Board of Directors Non-Employee Director Compensation Policy and
are each eligible to receive an annual cash retainer of
$40,000 for service on the Board and
an annual options award with an aggregate grant date fair value of
$100,000. The Company intends to
enter into customary indemnification agreements with each of Mr.
Huennekens and Mr. Moore.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
View original
content:http://www.prnewswire.com/news-releases/viewray-appoints-scott-huennekens-and-daniel-moore-to-its-board-of-directors-300595399.html
SOURCE ViewRay, Inc.